Kingworld Medicines Group Limited

Informe acción SEHK:1110

Capitalización de mercado: HK$319.9m

Kingworld Medicines Group Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Los beneficios de Kingworld Medicines Group han disminuido a una tasa media anual de -4.3%, mientras que en la industria Healthcare los beneficios crecieron en un 4.8% anualmente. Los ingresos han ido creciendo a una tasa media de 1% al año. La rentabilidad financiera de Kingworld Medicines Group es de 8.8%, y sus márgenes netos son de 3.5%.

Información clave

-4.3%

Tasa de crecimiento de los beneficios

-3.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 11.3%
Tasa de crecimiento de los ingresos1.0%
Rentabilidad financiera8.8%
Margen neto3.5%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Apr 23
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30
The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17
Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11
The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07
Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05
Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17
We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24
Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29
Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08
Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15
Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25
Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

Dec 18
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

Dec 05
We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Nov 22
What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Kingworld Medicines Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:1110 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 231,079382230
30 Sep 231,085372180
30 Jun 231,091362130
31 Mar 231,024292100
31 Dec 22958232060
30 Sep 22905292030
30 Jun 22852352000
31 Mar 22850331980
31 Dec 21847301960
30 Sep 21858262220
30 Jun 21868212480
31 Mar 21807172470
31 Dec 20745122460
30 Sep 20749162270
30 Jun 20752202080
31 Mar 20865322140
31 Dec 19978432200
30 Sep 191,010452210
30 Jun 191,041462220
31 Mar 191,060442370
31 Dec 181,079412520
30 Sep 181,079492640
30 Jun 181,079562770
31 Mar 181,055542640
31 Dec 171,031512510
30 Sep 171,088502400
30 Jun 171,145492290
31 Mar 171,099482270
31 Dec 161,054472250
30 Sep 16909412090
30 Jun 16764351930
31 Mar 16739341820
31 Dec 15714321710
30 Sep 15711341630
30 Jun 15708361550
31 Mar 15684371440
31 Dec 14660381340
30 Sep 14640431260
30 Jun 14619481190
31 Mar 14587481150
31 Dec 13555471120
30 Sep 13571471090
30 Jun 13587481060

Ingresos de calidad: 1110 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (3.5%) de 1110 son superiores a los del año pasado (2.4%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 1110 han disminuido en un 4.3% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 1110 en el último año (67.5%) supera su media de 5 años (-4.3% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 1110 en el último año (67.5%) superó al de la industria Healthcare 13.4%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 1110 (8.8%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target